Clinical Cancer Research, Vol 3, Issue 10 1721-1729, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma

LL Worth, N Jaffe, RS Benjamin, NE Papadopoulos, S Patel, AK Raymond, SF Jia, C Rodriguez, J Gano, MA Gianan and ES Kleinerman
Departments of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

A Phase II trial using interleukin 1alpha (IL-1alpha) and etoposide for patients with relapsed osteosarcoma (OS) was undertaken to assess the feasibility and tolerability of combination therapy with biotherapy and chemotherapy. Nine patients with histologically proven relapsed OS were treated with IL-1alpha immediately followed by etoposide daily for 5 days every 3 weeks. Surgical resection of lung metastasis or peripheral tumor was performed after two or three cycles. We observed three partial responses; disease was stable in another case. One case could not be evaluated. The side effects associated with combination therapy were as predicted from known side effects of the individual agents; however, more profound neutropenia was observed. Four patients exhibited clinical signs of capillary leak syndrome, i.e., hypotension, edema, and weight gain. The etiology of the capillary leak was unclear, because serum IL-1alpha, IL-2, tumor necrosis factor, and nitric oxide levels could not be used to predict which patients would develop capillary leak. Histological analysis of tumor specimens obtained after two or more courses of therapy showed changes consistent with a response to a biological response modifier: peripheral fibrosis surrounded the metastasis with infiltration of chronic and acute inflammatory cells. Because the response of relapsed OS to any type of salvage regimen has been poor, we interpret the clinical response of this therapy as good. However, the significant side effects associated with this therapy must also be taken into consideration before deciding to use this combination therapy. It is unfortunate that the study was stopped early due to halted production of IL-1alpha. If this agent is again manufactured for clinical use, we conclude that additional evaluation in patients with relapsed OS is warranted.

This article has been cited by other articles:

				H. Tsuchiya, Y. Kanazawa, M. E. Abdel-Wanis, N. Asada, S. Abe, K. Isu, T. Sugita, and K. Tomita Effect of Timing of Pulmonary Metastases Identification on Prognosis of Patients With Osteosarcoma: The Japanese Musculoskeletal Oncology Group Study J. Clin. Oncol., August 15, 2002; 20(16): 3470 - 3477. [Abstract] [Full Text] [PDF]